Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Slowdown in Covid-19 sales will further move Pfizer to M&A

<< Previous

Bullboard Posts

Next >>

Comment by Buckhenryon Oct 25, 2022 12:53pm

112 Views

Post# 35047159

RE:RE:Slowdown in Covid-19 sales will further move Pfizer to M&A

you folks are all over the place on wishing and hoping here. I've heard from 15 to 8 to 4 to 2.9 billion. the pattern here is no one knows squat but keep up the wishing.. its fun to read. blue skies

<< Previous

Bullboard Posts

Next >>

Why Chinese silver prices differ from London and New York